Detalhe da pesquisa
1.
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.
Gut
; 72(2): 295-305, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35902214
2.
Fecal Calprotectin in Gastrointestinal Disease.
Clin Chem
; 69(7): 699-710, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37228058
3.
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
Gut
; 70(10): 1884-1893, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33903149
4.
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
Gut
; 70(5): 865-875, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33753421
5.
Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
Gastroenterology
; 149(6): 1564-1574.e3, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26170138
6.
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
Lancet Gastroenterol Hepatol
; 9(5): 415-427, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402895
7.
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.
J Crohns Colitis
; 16(3): 389-397, 2022 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34473254
8.
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Nat Commun
; 13(1): 1379, 2022 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35296643
9.
Provision of care for pregnant women with IBD in the UK: the current landscape.
Frontline Gastroenterol
; 12(6): 487-492, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34712466